Clinical trials: Depressive Disorder, Major
Alcohol Dependence, Major Depression
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
STUDY OBJECTIVES: The primary objective of this study is to compare the safety and efficacy of acamprosate versus placebo in the treatment of alcohol dependence in adults with co-occurring mood or anxiety disorders (specifically…
- Conditions
- Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
- Trial name
- NCT00330174
- Testing
- Acamprosate
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
This is a study on the effectiveness, tolerability and safety of oral ziprasidone as monotherapy in patients with major depressive disorder (MDD).
- Trial name
- Geodon (NCT00555997)
- Testing
- Ziprasidone
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A Study of MD-120 in Patients With Depression
The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.
- Trial name
- NCT04345471
- Testing
- Desvenlafaxine 100 mg, Desvenlafaxine 50 mg
- Where
- Japan
- Volunteers
- 615 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Post Traumatic Stress Disorder, Schizophrenia
PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)
As in the general population, there is no clear standard of care within Veterans Affairs Medical Centers for treating posttraumatic stress disorder (PTSD) among individuals with severe mental illness (SMI).
- Conditions
- Post Traumatic Stress Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- PTSD/SMI (NCT01542229)
- Testing
- Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU), Treatment As Usual (TAU)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder, Irritable Bowel Syndrome
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder
The purpose of this study is to determine the safety and effectiveness of a nutritional supplement, the probiotic bacteria GanedenBC30.
- Trial name
- NCT01337609
- Testing
- Ganeden BC30
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Depression
Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
The primary study comparing effectiveness for suicidal ideation and/or behavior of two antidepressant medications in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts has been…
- Trial name
- NCT00429169
- Testing
- Paroxetine, Bupropion
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
- Trial name
- NCT01432457
- Testing
- desvenlafaxine succinate sustained-release 50 mg/day, desvenlafaxine succinate sustained-release 100 mg/day
- Where
- 61 sites in United States
- Volunteers
- 924 people
- Sponsor
- Pfizer
Major Depressive Disorder
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous…
- Trial name
- NCT01667926
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Major Depression, End Stage Renal Disease
Bupropion for Depression in ESRD Patients on Hemodialysis
The proposed study will evaluate the response and remission rates for major depressive disorder (MDD) in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD) treated with bupropion or fluoxetine for 12…
- Trial name
- NCT02238977
- Testing
- Fluoxetine, Bupropion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Major Depressive Disorder, Depression
Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)
The objective of this clinical trial is to evaluate whether an anti-inflammatory medication, pentoxifylline, reduces depressive symptoms and improves artery function.
- Conditions
- Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD)
- Trial name
- INFLAMED (NCT01625845)
- Testing
- Pentoxifylline, Standard Treatment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Major Depressive Disorder
ANC-501 in the Treatment of Adults With Major Depressive Disorder
A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
- Trial name
- NCT05439603
- Testing
- ANC-501
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Hepatitis C, Chronic
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
The purpose of this study is to determine whether the use of an antidepressant (escitalopram) can prevent depressive episodes that appear during the treatment with peg-interferon and ribavirin in patients with chronic hepatitis C.
- Trial name
- NCT00166296
- Testing
- Escitalopram
- Where
- 15 sites in Spain
- Volunteers
- 133 people
- Sponsor
- Germans Trias i Pujol Hospital
Major Depressive Disorder
The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD
Objectives: 1. To evaluate the relationship between improvement of Hamilton Depression Rating Scale (HAMD) score and basal SERT availability (binding potential) for the prognosis of MDD subjects being treated with Sertraline HCl…
- Trial name
- STAPMDDTDM (NCT02473783)
- Testing
- Sertraline HCl, I-123-ADAM SPECT
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tri-Service General Hospital (TSGH)
Major Depressive Disorder
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood.
- Trial name
- NCT01804270
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Paul E. Croarkin
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda